Stocks Roundup – Dyax Corp. (DYAX), Baxter International Inc. (BAX), Spectrum Pharmaceuticals, Inc. (SPPI), Salix Pharmaceuticals, Ltd. (SLXP)

Submitted By on May 10, 2014 - 01:58 PM

Birmingham, West Midlands – (TechSonian) –10 May 2014 — Dyax Corp. (NASDAQ:DYAX), reported financial results for the first quarter ended March 31, 2014. Total revenues for the first quarter ended March 31, 2014 were $14.1 million, as compared to $12.0 million for the comparable quarter in 2013. These include KALBITOR net sales of $12.5 million and $8.6 million for the first quarters of 2014 and 2013, respectively. For the quarter ended March 31, 2014, the Company announced a net loss of $5.7 million or $0.05 per share, as compared to a net loss of $11.2 million or $0.11 per share for the comparable quarter in 2013.

Dyax Corp.(NASDAQ:DYAX) gaining 3.40% and closed at $6.38 on a traded volume of 1.47 million shares, in comparison to 1.73 million shares of average trading volume. The company has a total market capitalization of $866.41 million.

For How Long DYAX will fight for Profitability? Read This Trend Analysis report

Baxter International Inc. (NYSE:BAX), recently declared that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation SIGMA Spectrum Infusion Pump with Master Drug Library.

Baxter International Inc. (NYSE:BAX) surged 0.31% and closed at $75.06 on a traded volume of 1.46 million shares, whereas its average trading volume is 3.93 million shares. The Intra-day range for the stock is $74.17 and $75.11.

For How Long BAX Gloss will Attract Investors? Find out via this report

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), recently revealed that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2014 Health Care Conference being held at The Encore at Wynn in Las Vegas, Nevada. The Company presentation is on Tuesday, May 13, 2014, at 2:20 PM PT.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) increase 9.77% and closed at $7.30. The 52-week range for the stock is $6.36 and $10.32 and during the previous trading session the stock touched its highest price at $7.33. Its introductory price for the day was $6.69, with the overall traded volume of 1.45 million shares.

Why Should Investors Buy SPPI After the Recent Fall? Just Go Here and Find Out

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), recently proclaimed financial and operating results for the first quarter ended March 31, 2014, and other business updates. For the first quarter of 2014, as compared to the first quarter of 2013, total net product revenue increased 90% to $384.4 million. EBITDA increased 114% to $149.2 million. Non-GAAP EPS increased 67% to $1.05 per diluted share. GAAP net loss includes $86.4 million in Santarus transaction costs.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) decline -2.13% and closed at $103.56. The 52-week range for the stock is $52 and $120 and during the previous trading session the stock touched its highest price at $105.53. Its introductory price for the day was $101.70, with the overall traded volume of 1.45 million shares.

Why Should Investors Buy SLXP After the Recent Fall? Just Go Here and Find Out